Study of Higher vs Standard Doses of Prucalopride to Help Gut Recovery After Elective Colorectal Surgery

What this Trial Is About

Postoperative ileus POI is a common problem after abdominal surgery, especially colorectal operations, causing symptoms like nausea, vomiting, bloating, and delayed bowel movements. Managing POI is difficult, with few drug options available. This research evaluates if higher doses of prucalopride, a selective serotonin 5-HT4 receptor agonist, can help improve bowel function and shorten hospital stay after elective colorectal surgery, comparing 4 mg and 2 mg doses with placebo. Participants will be randomly assigned to receive either standard care, prucalopride 2 mg, or prucalopride 4 mg taken before surgery. The study is double-blind, meaning neither participants nor researchers know who receives which treatment. The goal is to see if the higher 4 mg dose leads to faster recovery of gut function and reduced hospital time compared to the lower dose or no prucalopride. During the trial, participants will be monitored for the time it takes to pass their first stool and tolerate food within 7 days after surgery. Additional outcomes include time to first gas passage and incidence of prolonged POI. The study includes careful evaluations and follows patients for one week post-operation to assess recovery speed and safety. The total participation spans this immediate postoperative period, focusing on gut function return and hospital stay length.

Impact of Varying Doses of Prucalopride on Improving Gut Function Recovery After Elective Colorectal Surgery